Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy.
Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy.
复制标题
DOI：
10.1097/ajp.0b013e3181f195ba
复制
发表时间：
2010-11
期刊：
影响因子：
--
通讯作者：
Jamison RN
中科院分区：
文献类型：
--
作者：
Butler SF;Budman SH;Fanciullo GJ;Jamison RN
当前阿片类药物滥用测量（COMM）是一种自我报告测量，用于测量慢性疼痛患者服用阿片类药物治疗疼痛的异常药物相关行为的风险。它的开发是为了补充阿片类药物滥用潜力的预测性筛查，并提高临床医生定期评估患者阿片类药物滥用风险的能力。本研究的目的是交叉验证COMM与慢性非癌性疼痛患者的新样本。从美国的五个疼痛管理中心招募了226名（N=226）服用阿片类药物治疗疼痛的参与者。受试者完成了17项问卷调查和一系列自我报告测试。患者由其主治医师评定，进行尿液毒理学筛查，并根据异常药物行为指数进行分类。通过曲线下面积（AUC）测量的交叉验证的信度和预测效度发现非常显著（AUC =.79），与原始验证研究中获得的AUC （AUC =.81）没有显著差异。信度系数α为。83、这与…在原始样品中得到86。交叉验证的结果表明，COMM的心理测量参数并不仅仅基于初始验证样本的独特特征。在慢性疼痛患者中，COMM似乎是一种可靠有效的筛查工具，可以帮助检测当前异常的药物相关行为。
The Current Opioid Misuse Measure (COMM) is a self-report measure of risk for aberrant medication related behavior among persons with chronic pain who are prescribed opioids for pain. It was developed to complement predictive screeners of opioid misuse potential and improve a clinician's ability to periodically assess a patient's risk for opioid misuse. The aim of this study was to cross validate the COMM with a new sample of chronic noncancer pain patients. Two hundred and twenty six (N=226) participants prescribed opioids for pain were recruited from five pain management centers in the US. Subjects completed the 17-item COMM and a series of self-report measures. Patients were rated by their treating physician, had a urine toxicology screen, and were classified on the Aberrant Drug Behavior index. The reliability and predictive validity in this cross validation as measured by the area under the curve (AUC) were found to be highly significant (AUC =.79) and not significantly different from the AUC obtained in the original validation study (AUC =.81). Reliability (coefficient α) was .83, which is comparable to the .86 obtained in the original sample. Results of the cross validation suggest that the psychometric parameters of the COMM are not based solely on unique characteristics of the initial validation sample. The COMM appears to be a reliable and valid screening tool to help detect current aberrant drug-related behavior among chronic pain patients.